How COVID-19 Causes Myocarditis and Who Is Most at Risk

SARS-CoV-2 infection can inflame the heart muscle, a condition called myocarditis, and it does so at rates substantially higher than those seen before the pandemic. One large review estimated that COVID raised the incidence of myocarditis at least fifteen-fold over pre-pandemic levels, though the condition still affects a small fraction of everyone who gets infected. The relationship between the virus and the heart turns out to be more layered than a simple “the virus attacks heart cells” story, involving direct viral damage, an immune system that can overshoot, and blood-vessel dysfunction that starves the heart of oxygen.

How SARS-CoV-2 Damages the Heart

The virus enters human cells by latching onto a protein called ACE2, which sits on the surface of cells throughout the body, including heart muscle cells (cardiomyocytes).¹ Once inside a cardiomyocyte, the virus can directly injure the cell, triggering inflammation in the surrounding tissue. But direct viral invasion is only one piece of the puzzle. Researchers have identified several overlapping mechanisms that contribute to heart damage during COVID.

The immune response itself can become a problem. When the body detects the virus, it floods the area with inflammatory signaling molecules called cytokines. In severe cases, this response spirals out of control, damaging heart tissue that the virus may not have even reached directly.² The combination of direct viral damage and this runaway immune reaction is what makes COVID-related myocarditis particularly concerning.³

A third route involves the blood vessels themselves. COVID can injure the endothelium, the thin lining inside blood vessels, which impairs blood flow and promotes clotting. This endothelial dysfunction can reduce oxygen delivery to the heart and create tiny clots in the heart’s microvascular network.⁴ When heart cells are starved of oxygen on top of everything else, the damage compounds. Some researchers have also highlighted increased sympathetic nervous system activity during severe illness, which further stresses the heart and worsens microvascular dysfunction.⁵

People with diabetes may face added vulnerability. In diabetic hearts, ACE2 expression is upregulated, and the protein can be altered by a process called glycation. Both changes appear to make it easier for the virus to enter heart cells, potentially explaining why people with diabetes have been hit harder by cardiac complications of COVID.⁶

How Common Is COVID-Related Myocarditis

The numbers vary depending on how you look and who you study, but the broad picture is consistent: COVID raises the risk of myocarditis well above baseline, yet the absolute number of affected people remains relatively small. Before the pandemic, myocarditis occurred in roughly 1 to 10 people per 100,000 per year. With COVID, estimates ranged from about 150 to 4,000 per 100,000, depending on the population studied and how aggressively clinicians looked for it.⁷

Among hospitalized COVID patients specifically, the rates are easier to pin down. A German nationwide analysis of over 176,000 COVID hospitalizations in 2020 found myocarditis in about 1.3 per 1,000 hospitalized cases.⁸ A separate multicenter study pegged the prevalence of definite or probable acute myocarditis at about 2.4 per 1,000 COVID hospitalizations, rising to around 4 per 1,000 when possible cases were included.⁹ Those numbers track reasonably well with one another and tell the same story: roughly 1 to 4 hospitalized COVID patients per thousand develop recognizable myocarditis.

The risk does not vanish once you recover from the acute infection. A meta-analysis following COVID survivors for an average of about nine and a half months found that those who had recovered from COVID were roughly five times more likely to develop myocarditis compared with people who had never been infected. In absolute terms, myocarditis occurred in about 0.21 per 1,000 COVID survivors versus 0.09 per 1,000 controls.¹⁰ That relative risk sounds alarming, but the absolute numbers remain low.

Who Faces the Highest Risk

Men and younger adults are disproportionately affected. In a systematic review and meta-analysis examining myocarditis after both COVID infection and vaccination, about 61% of those who developed myocarditis were male, and regression analysis confirmed that being male and younger were associated with higher risk.¹¹ This male predominance is not unique to COVID; viral myocarditis in general tends to skew male, likely due to hormonal and immune differences.

Older men may carry a subtler form of risk. A study tracking troponin levels (a protein released when heart cells are damaged) found that men older than 54 with even mild COVID had persistently elevated troponin for months after infection, lasting through 14 months of follow-up. This low-grade elevation suggests ongoing or unresolved heart muscle injury even in people who felt like they had recovered.¹²

Genetics may also play a role. A whole-exome sequencing study of hospitalized COVID patients found enrichment of rare variants in genes associated with cardiomyopathy, particularly in patients of African or Hispanic ancestry. The hypothesis is that these genetic variants were previously silent but became clinically relevant under the extreme cardiac stress imposed by severe COVID.¹³ This line of research is still early, but it could help explain why some people develop severe cardiac complications while others with similar infections do not.

Symptoms and Diagnosis

COVID-related myocarditis can present with chest pain, shortness of breath, palpitations, fatigue, or reduced exercise tolerance. The difficulty is that many of these symptoms overlap with COVID itself, making it easy to miss the cardiac component. Some patients have no heart-related symptoms at all, which is why screening has become critical in certain populations like competitive athletes.

Cardiac MRI has emerged as the key diagnostic tool. It can reveal both diffuse and focal patterns of heart injury. Some studies have found widespread inflammation visible as elevated T1 and T2 values on imaging, indicating fibrosis or swelling throughout the heart muscle. Others have shown more localized damage in patterns characteristic of non-ischemic injury, such as patchy scarring in the mid-wall or outer surface of the heart.¹⁴ The variability in imaging findings suggests that COVID-related myocarditis is not a single uniform condition but a spectrum.

Getting a firm diagnosis can be challenging. In one study of patients referred for suspected myocarditis after COVID, only 2% had confirmed acute myocarditis meeting formal imaging criteria along with supportive blood-test results. Another 14% had suspicious findings on cardiac MRI but ultimately could not be confirmed as definite myocarditis under the established diagnostic standards.¹⁵ This highlights a gray zone that clinicians navigate regularly: cardiac MRI abnormalities are common after COVID, but the threshold for calling something “myocarditis” remains a judgment call.

Autopsy data add another layer. In a pathology study of patients who died with COVID, lymphocytic myocarditis, the classic form of viral heart inflammation, was found in about 14% of cases. In most of these, the infiltrating immune cells were predominantly CD4 T cells.¹⁶ Separately, a meta-analysis of post-mortem heart tissue found SARS-CoV-2 genetic material in over 60% of patients who died from COVID.¹⁷ The virus clearly reaches the heart, but the presence of viral RNA does not always correlate with the kind of inflammation that would be diagnosed as myocarditis in a living patient.

The Hidden Cases in Athletes

Some of the most eye-opening data on COVID myocarditis came from competitive sports. When the Big Ten athletic conference screened over 1,500 college athletes who had recovered from COVID using cardiac MRI regardless of symptoms, 2.3% were found to have myocarditis. Most of these cases, 28 out of 37, were subclinical, meaning the athletes had no cardiac symptoms at all. If screening had relied on symptoms alone, only about 0.3% would have been caught, a sevenfold difference.¹⁸

A study of professional athletes found a lower rate. Out of 789 athletes screened after COVID, downstream testing confirmed myocarditis in 0.4% and pericarditis in an additional 0.3%.¹⁹ Another evaluation of 145 competitive student athletes found MRI evidence of myocarditis in 1.4%, including in one athlete who had been entirely asymptomatic and was tested only as part of routine screening.²⁰

These findings matter because exercising with undiagnosed myocarditis is dangerous. Inflamed heart tissue is electrically unstable, and intense physical exertion can trigger life-threatening arrhythmias. The athlete data make a strong case that COVID-related myocarditis is often silent and that relying on symptoms alone will miss most of it.

COVID Myocarditis Versus Vaccine-Related Myocarditis

This comparison became one of the most intensely studied questions in cardiology during the pandemic, and the answer is consistently in one direction: the risk of myocarditis from COVID infection is substantially greater than from vaccination. One pragmatic review estimated the incidence of myocarditis at about 11 per 100,000 COVID infections compared with roughly 2.7 per 100,000 people after mRNA vaccination.²¹

A large English study put this in sharper terms. The rate of myocarditis in the month following a positive SARS-CoV-2 test was over eleven times the background rate in unvaccinated individuals, whereas the rate after a first or second dose of BNT162b2 (Pfizer) was about one and a half times the background rate. Even after a booster dose, the vaccine-associated risk was roughly 1.7 times baseline, still far below the infection-associated risk.²²

The long-term outcomes also differ. A study comparing patients hospitalized for myocarditis from different causes found that post-vaccine myocarditis had the best prognosis: only about 0.2% of those patients died during follow-up. Post-COVID myocarditis carried a 1.3% death rate over 18 months, identical to conventional (non-COVID, non-vaccine) myocarditis. Rehospitalization for other cardiovascular events was also higher after COVID-related myocarditis (about 7.4%) than after vaccine-related myocarditis (about 2.7%).²³ In other words, vaccine-triggered myocarditis tends to be milder and more self-limiting than the version caused by the virus itself.

Children, MIS-C, and the Heart

In children, the cardiac picture looked different from adults. Rather than straightforward viral myocarditis, COVID triggered a delayed inflammatory syndrome called Multisystem Inflammatory Syndrome in Children (MIS-C), which has been characterized as a post-viral myocarditis combined with widespread blood-vessel inflammation.²⁴ MIS-C typically appeared weeks after the initial infection, often in children who had mild or even asymptomatic COVID.

Myocarditis has been a common feature of MIS-C since the condition was first recognized in 2020.²⁵ In a multicenter international registry of 111 children with MIS-C who underwent cardiac MRI, 18% met formal imaging criteria for acute myocarditis. Among those with MRI-confirmed myocarditis, the condition was associated with more severe illness, including a sixfold increased odds of needing mechanical circulatory support.²⁶

Treatment for post-COVID pediatric myocarditis has leaned on immunomodulatory therapy. In one study from a tertiary-care setting, combining intravenous immunoglobulin (IVIG) with steroids was used more frequently in post-COVID cases than in conventional myocarditis, and this combination was associated with significantly reduced mortality compared with IVIG alone.²⁷

Treatment in Adults

There is no single approved therapy for COVID-related myocarditis, and treatment has largely been guided by case reports, small series, and clinical judgment. The evidence, thin as it is, has pointed toward corticosteroids as the most commonly used and apparently beneficial option. A systematic review of corticosteroid use in COVID myocarditis found that about 72% of treated patients experienced major clinical improvement. Methylprednisolone was the most frequently used steroid, given intravenously, with treatment courses ranging from one to fourteen days.²⁸

Other agents that have been tried include IL-6 inhibitors, IVIG, and colchicine, but the evidence for these remains uncertain. One early systematic review noted that steroid therapy appeared to produce favorable outcomes but cautioned that treatment decisions still need to be made on a case-by-case basis until larger trials are available.²⁹ Standard heart-failure medications like ACE inhibitors, beta-blockers, and diuretics are used as needed to support heart function during recovery, but these treat the consequences of myocarditis rather than the inflammation itself.

Long-Term Prognosis

Most people who develop COVID-related myocarditis recover, but the condition is not entirely benign. As noted in the comparison with vaccine-related myocarditis, the 18-month mortality rate for post-COVID myocarditis was about 1.3%, with roughly 4% being rehospitalized for recurrent heart inflammation and about 7.4% for other cardiovascular events.³⁰ These numbers are essentially identical to conventional myocarditis caused by other viruses, which suggests that once COVID-related myocarditis develops, it follows a familiar clinical trajectory rather than being a uniquely dangerous form of the disease.

The persistent troponin elevations seen in older men after even mild COVID hint that some degree of subclinical heart injury may linger in a broader population than just those diagnosed with myocarditis. Whether this low-level damage leads to meaningful long-term heart problems remains an open question. The concern is real but not yet well quantified.

Returning to Exercise After COVID Myocarditis

For athletes and active people, the question of when to start exercising again after myocarditis is critical. Current guidelines recommend a period of exercise restriction followed by comprehensive reassessment before returning to play. Cardiac MRI is central to the clearance process, because it can detect residual inflammation or scarring that blood tests and EKGs might miss.³¹

Timelines vary by severity. In one published case, a collegiate athlete diagnosed with COVID-related myocarditis was gradually allowed back into sport and returned to competition at nine months, successfully completing her season.³² That is longer than many athletes hope for, but myocarditis remains one of the leading causes of sudden cardiac death in young athletes, so caution is warranted. The general recommendation is at least three to six months of restricted activity, with clearance contingent on normal cardiac imaging and the absence of arrhythmias during monitored exercise testing.³³

For non-athletes who had COVID myocarditis and want to return to recreational exercise, the same principles apply in less formalized fashion. Gradual resumption, attention to any new symptoms like chest pain or unusual breathlessness during exertion, and follow-up with a cardiologist are the standard advice. Pushing through symptoms is the one thing every guideline agrees you should not do.